Forma Therapeutics CEO and leadership

With over 25 years’ global experience in product development and commercial leadership across a wide range of therapeutic areas within the biotech and pharmaceutical industry, Frank joined as Chief Executive Officer of Forma Therapeutics in March of 2019.

Most recently serving as Senior Vice President, Global Product Strategy and Therapeutic Area Head for the Immunology, Ophthalmology and Infectious Diseases at Genentech, a member of the Roche Group, he was responsible for driving development and commercial strategy for a broad portfolio of molecules in development and for global in-line product sales of more than $11 Billion. Frank’s 13-year career path at Genentech included leadership positions of increasing scope and responsibility for delivering transformative medicines to patients. Previously, as Vice President of the HER2/Breast Cancer Franchise, Frank was responsible for the US P&L for Herceptin®, Perjeta® and Kadcyla®, driving revenues over $4 Billion and launching the first HER2 neoadjuvant indication shaping a new market and treatment paradigm for early HER2 breast cancer patients. As Vice President of Oral Oncolytics, Frank held P&L responsibility for Tarceva®, Zelboraf®, Erivedge® and Xeloda®, advancing personalized medicine for cancer patients with EGFR+ NSCLC and BRAF+ melanoma, and establishing a new treatment option for patients with advanced basal cell carcinoma. Other roles at Genentech included Franchise Head, Transplant and Tamiflu® as well as Director of Marketing for Ophthalmology and Respiratory. Prior to joining Genentech, Frank spent approximately 13 years across Novartis, Janssen and Eli Lilly in engineering, manufacturing, sales/marketing and business development.

Frank received a bachelor’s degree in chemical engineering from Vanderbilt University and an M.B.A. in Marketing and Finance from the Wharton Graduate School of Business. He previously served on the Board of Directors of the Genentech Foundation.

Dave Cook is a scientist and entrepreneur who has held senior operating and management positions in the biotechnology industry for more than 25 years. Prior to joining Forma, Dave served as chief scientific officer for Seres Therapeutics. He played a key role in the strategy and fundraising in the microbiome field for Seres, and he was integral to the translation to the clinic of drugs for C. difficile, irritable bowel disease and immuno-oncology. Prior to Seres, he was the chief operating officer for The International AIDS Vaccine Initiative (IAVI), a global not-for-profit R&D organization whose mission is to develop a globally accessible HIV vaccine. Dave was the founding CEO at Anza Therapeutics, a start-up developing a novel microbial vaccine platform to induce cellular immune responses to fight or prevent cancer and chronic infections. Before launching Anza, Dave held positions of increasing responsibility at the biotechnology corporations Cerus and Eligix, with oversight over R&D, program management, manufacturing and clinical and regulatory affairs.

Dave received his undergraduate degree from Harvard College and his Ph.D. in chemistry from the University of California, Berkeley.

Todd joined Forma in September of 2019 with over 25 years of financial experience in the biotechnology and pharmaceutical industries. He most recently served as Chief Financial Officer for Synlogic (NASDAQ:SYBX) where he directed the company’s financial strategy and management as well as facilities and information systems. Prior to Synlogic, Todd served as Senior Vice President and Chief Financial Officer at Forum Pharmaceuticals, where he was responsible for finance, operations and information systems during their pursuit of innovative therapies for schizophrenia and Alzheimer’s disease. Prior to Forum, Todd was the Chief Financial Officer of Millennium Pharmaceuticals, Inc., now Takeda Oncology, where he was responsible for management of the company’s financial resources, corporate planning, financial reporting and compliance.

Todd earned a Bachelor of Science degree in Electrical Engineering from Lafayette College and an M.B.A. from the Tepper School of Management at Carnegie Mellon University.

With over 25 years’ global experience in product development and commercial leadership across a wide range of therapeutic areas within the biotech and pharmaceutical industry, Frank joined as Chief Executive Officer of Forma Therapeutics in March of 2019.

Most recently serving as Senior Vice President, Global Product Strategy and Therapeutic Area Head for the Immunology, Ophthalmology and Infectious Diseases at Genentech, a member of the Roche Group, he was responsible for driving development and commercial strategy for a broad portfolio of molecules in development and for global in-line product sales of more than $11 Billion. Frank’s 13-year career path at Genentech included leadership positions of increasing scope and responsibility for delivering transformative medicines to patients. Previously, as Vice President of the HER2/Breast Cancer Franchise, Frank was responsible for the US P&L for Herceptin®, Perjeta® and Kadcyla®, driving revenues over $4 Billion and launching the first HER2 neoadjuvant indication shaping a new market and treatment paradigm for early HER2 breast cancer patients. As Vice President of Oral Oncolytics, Frank held P&L responsibility for Tarceva®, Zelboraf®, Erivedge® and Xeloda®, advancing personalized medicine for cancer patients with EGFR+ NSCLC and BRAF+ melanoma, and establishing a new treatment option for patients with advanced basal cell carcinoma. Other roles at Genentech included Franchise Head, Transplant and Tamiflu® as well as Director of Marketing for Ophthalmology and Respiratory. Prior to joining Genentech, Frank spent approximately 13 years across Novartis, Janssen and Eli Lilly in engineering, manufacturing, sales/marketing and business development.

Frank received a bachelor’s degree in chemical engineering from Vanderbilt University and an M.B.A. in Marketing and Finance from the Wharton Graduate School of Business. He previously served on the Board of Directors of the Genentech Foundation.